Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06256770
Other study ID # zhangyi2023
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2022
Est. completion date December 1, 2024

Study information

Verified date February 2023
Source Tianjin Eye Hospital
Contact Xinyu Yang
Phone 022-27313336
Email yxydoctor0725@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate the short-term efficacy and safety of scleral contact lens in the clinical treatment of patients with irregular astigmatism after corneal transplantation by analyzing ocular parameters and ocular surface conditions of patients after corneal transplantation.


Recruitment information / eligibility

Status Recruiting
Enrollment 176
Est. completion date December 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 8 Years to 55 Years
Eligibility Inclusion Criteria: 1.8 = age = 55 years old;2.The diopter of one or both eyes is -25.00~+25.00 D (including -25.00D and +25.00D), and corneal astigmatism caused by any reason (including keratoconus, irregular cornea) =0.75D. Exclusion Criteria: 1.Patients who are judged by the investigator to be unsuitable for corneal endothelial cells;2.Dry eye ;3.Abnormal IOP ;4.Overt strabismus;5.Bacterial, fungal, viral and other active corneal infections;6. Being used may cause dry eyes or affect the eyeball or affect vision or affect the angle drugs such as membrane curvature;7.Corneal sensory, active corneal lesions;8.Conventional slit lamp microscopy and ophthalmoscopy, corneal diseases, iris cyclitis, chronic uveitis, cataract and vitreoretina related eye diseases disease or active and progressive disease;9.Other eye diseases: such as dacryocystitis, eyelid diseases and eyelid abnormalities or infections, eye muscle-related diseases, optic pathway diseases, glaucoma;10.Patients with systemic diseases that cause immunocompromise;History of allergy to contact lenses or contact lens care solution;11.History of allergy to contact lenses or contact lens care solution;12.Pregnant, lactating or planning to become pregnant in the near future;13.Subjects who are considered by the investigator to be unable to wear rigid contact lenses after comprehensively considering the corneal parameters, morphological characteristics and refractive examination results of the examination results;14.Those who have worn hard contact lenses within 30 days or soft hydrophilic contact lenses within 10 days;15.Those who participated in other drug clinical trials 3 months before screening and participated in other medical device clinical trials within 30 days;16.one-eyed patients;17.Those who have a strong sense of foreign body and cannot tolerate it and have poor compliance, and cannot be timely and regular to the medical institution for medical treatment as required;18.Other conditions judged by the investigator that the patient is not suitable for enrollment.

Study Design


Locations

Country Name City State
China Tianjin Eye Hospital Tianjin Tianjin

Sponsors (1)

Lead Sponsor Collaborator
Tianjin Eye Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement of Best Corrected Vision Acuity The percentage of eyes with best corrected visual acuity improved by two lines or more (compared to best corrected visual acuity with glasses) or 5.0 or greater (standard logarithmic visual acuity chart) after 1 month ± 7 days of contact lens wear. One year
Secondary Best Corrected Visual Acuity and Refraction with Contact Lenses Contact lenses for best corrected visual acuity. List the visual acuity of wearing glasses 7 days±3 days,1 month±7 days, and 3 months±14 days after wearing glasses. To provide the statistical analysis results of spectacle visual acuity in the experimental group and the control group;
Diopter. The diopters of 7 days±3 days,1 month±7 days, and 3 months±14 days after wearing glasses were listed, and the results of diopter analysis in the experimental group and the control group were provided.
One year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04067973 - Impact of Prematurity on the Optic Nerve
Completed NCT04828057 - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT00346450 - Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Phase 3
Completed NCT04351100 - Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
Completed NCT03659955 - Autologous Blood Treatment for Ocular Surface Disease N/A
Completed NCT04536129 - Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure N/A
Completed NCT01254370 - Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease Phase 2
Completed NCT00554411 - Assessing Ocular Surface Changes After Changing Glaucoma Medications N/A
Completed NCT03769454 - A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers Phase 1
Completed NCT04673604 - From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy N/A
Not yet recruiting NCT06370585 - Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF Phase 1
Withdrawn NCT04735510 - Novel Use of Restasis and PROSE Devices Phase 3
Suspended NCT00348114 - Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency Phase 2
Recruiting NCT04010422 - Ocular Function in Autism Spectrum Disorder
Completed NCT05528016 - Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty N/A
Completed NCT04452279 - Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification N/A
Completed NCT04535388 - LK Scleral Lens for Patients With Intractable Ocular Surface Diseases N/A
Recruiting NCT06298890 - The Pattern of Dry Eye Disease After Cataract Surgery
Completed NCT02802137 - 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy Phase 4